Treatment of Rapidly Progressive Vitiligo When Oral Steroid Minipulse Therapy Fails to Arrest Disease Progression

Clinical Scenario

This protocol applies to patients with extensive, rapidly spreading vitiligo — disease that is actively progressing and has not been brought under control by first-line treatment. The clinical priority is halting ongoing depigmentation in a patient whose condition continues to advance despite initial intervention.

Prior Treatment & Failure Condition

First-line management of rapidly progressive vitiligo centres on oral steroid minipulse (OMP) therapy, with or without NB-UVB phototherapy. Escalation to this protocol is indicated when OMP-based treatment does not achieve its primary goal: arrest of disease activity — that is, when active depigmentation and spread continue. This protocol addresses what to do next.

Next-Line Approach (Partial Overview)

When disease continues to spread despite OMP, the approach shifts to systemic immunomodulating agents as the next class of intervention. Depending on availability and regulatory status, agents from a more recently approved therapeutic class may also be considered. The specific agents, selection rationale, and any sequencing are contained in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.19450

The experts recommend oral mini-pulses of moderate doses of betamethasone (5 mg) or dexamethasone (2.5–5 mg depending on body weight) twice weekly on 2 consecutive days per week for the treatment of rapidly progressive vitiligo to stop disease progression, after careful consideration of the risks and benefits.
OMP therapy in patients with extensive and rapidly spreading disease was reported to arrest the activity of the disease in more than 80% of patients.
Methotrexate, cyclosporine, azathioprine and minocycline can be used in patients with progressive vitiligo, although strong evidence for efficiency and safety is lacking.
Systemic JAK inhibitors are promising, and their use can be considered when available and approved by regulatory agencies.

View source ↗